EUROAPI Logo
FR0014008VX5

EUROAPI

Ins Portfolio

Kurse werden geladen...

Prognose

Kaufen
  0
Halten
  0
Verkaufen
  1

Scoring-Modelle

Dividenden-Strategie 0 / 15
HGI-Strategie 5 / 18
Levermann-Strategie -4 / 13
Powered by aktien.guide

News

  • Foto von Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi
    18.09. - 16:00 Uhr

    Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi

    SAN FRANCISCO--(BUSINESS WIRE)-- #gxp--Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon Execute, an innovative eBR (Electronic Batch Record) software product, developed in collaboration with Euroapi, a leading global API manufacturer. This collaboration was born out of the need to digitize operations towards more data-driven manufacturing - focusing on the essential user needs while avoiding. » Mehr auf businesswire.com

  • Foto von EUROAPI - Availability of 2024 Half-Year Financial Report
    05.08. - 06:00 Uhr

    EUROAPI - Availability of 2024 Half-Year Financial Report

    Paris, 05 August, 2024 – EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and downloading on EUROAPI's website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. » Mehr auf globenewswire.com

  • Foto von EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1
    26.06. - 15:40 Uhr

    EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1

    Press Release Agreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit Facility 75 to 80 M€ annual run-rate incremental Core EBITDA targeted by the end of 2027, driven by the end of higher value API and CDMO offering, a streamlined industrial footprint, and significant cost reductions Brindisi site expected to progressively resume shipments and production during Q3 2024 “FOCUS-27 is leading EUROAPI to a more agile, value-added, and rightsized business model. It will significantly improve the company's competitiveness and set the stage for long-term sustainable, profitable growth,” says Ludwig de Mot, Chief Executive Officer. » Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte EUROAPI einen Umsatz von 225,45 Mio und ein Nettoeinkommen von 17,40 Mio
(EUR) Juni 2024
YOY
Umsatz 225,45 Mio 54,60%
Bruttoeinkommen 49,00 Mio 48,04%
Nettoeinkommen 17,40 Mio 127,71%
EBITDA 26,05 Mio 53,73%

Fundamentaldaten

Metrik Wert
Marktkapitalisierung
342,48 Mio
Anzahl Aktien
95,26 Mio
52 Wochen-Hoch/Tief
11,56 - 2,50
Dividenden Nein
Beta
0,56
KGV (PE Ratio)
0,82
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,38
KUV (PS Ratio)
0,28

Unternehmensprofil

Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.

Name
EUROAPI
CEO
Ludwig De Mot
Sitz Paris,
Frankreich
Website
Börsengang
06.05.2022
Mitarbeiter 3.650

Ticker Symbole

Börse Symbol
Euronext
EAPI.PA
Pnk
EAPIF
Frankfurt
940.F
Düsseldorf
940.DU
London
0EAP.L
Paris
EAPI.PA
München
940.MU
🍪

Parqet nutzt Cookies. Erfahre Mehr